MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
3. Government ... Funders, Regulators, Policy Makers, Conveners
*Government: International
Europe
*Europe: Regions
*Western Europe
Switzerland
*Industry: Switzerland
IMMUNOVANT SCIENCES GmbH (Nasdaq: IMVT)*
Organization & Developments: Immunovant
Parents
IMMUNOVANT SCIENCES GmbH (Nasdaq: IMVT)*
Children
2021: Immunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401
2022: Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset
2023: Immunovant: argenx At A 10% Valuation, Initiating With A Buy Rating_ seekingalpha.com
2023: Immunovant: Data Sizzles, But The Steak Isn't Done Yet (Rating Upgrade)
2024: Immunovant Advances IMVT-1402 with 5 IND Clearances Despite Widening Losses
2024: Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses
2024: Immunovant: An Intriguing And Developing Story
2024: Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study_ seekingalpha.com
2024: Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)
2024: Immunovant: Switching Lead Candidates Increases Risk
2024: Immunovant's SWOT analysis: biotech stock poised for growth in Graves' disease
2025: Immunovant: Navigating The Complexities Of The FcRn Landscape (Downgrade)
Jumps
Finance & Acquisitions: Immunovant
Key People: Immunovant